Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 January 2024 | Story Leonie Bolleurs | Photo Sonia Small
Prof Corinna Walsh
Prof Corinna Walsh says the PEA POD Infant Body Composition System works by directly measuring an infant’s body weight and volume, and then uses these measurements to calculate the body fat percentage, fat mass, and fat-free mass.

Nutritional and growth patterns during early life have been associated with health, development, and well-being throughout the life cycle. It is also associated with risks for developing obesity and non-communicable diseases, such as cardiometabolic diseases, later in life. These are the findings of Prof Corinna Walsh, Professor in the Department of Nutrition and Dietetics.

Maternal and child health

”In line with national priorities, a strong research focus area of the Faculty of Health Sciences and the School of Health and Rehabilitation Sciences is maternal and child health,” she says. She goes on to mention that the Department of Nutrition and Dietetics has established a reputable research programme. This programme focuses primarily on the nutritional status of pregnant women and how the early environment to which they are exposed during and after pregnancy affects short- and long-term health outcomes of the offspring.

“In our previous work, the assessment of birth outcomes of infants was, however, limited by the lack of equipment to analyse body composition. The research that we can conduct with the PEA POD® provides us with immense additional potential,” remarks Prof Walsh.

She explains, “The PEA POD Infant Body Composition System is an infant-sized air displacement plethysmography system. It works by directly measuring an infant’s body weight and volume, and then uses these measurements to calculate the body fat percentage, fat mass, and fat-free mass.

According to her, the assessment of body volume takes two minutes. “The PEA POD technique also does not require collection of any fluids and does not expose the infant to radiation. It can be performed as often as required without any risks and be used up to a maximum of 8-10 kg body weight, from birth to about eight months,” she says.

Advanced technology

In the context of research on infant body weight and composition, there is a need for accurate measurement techniques that can differentiate between fat mass and fat-free mass. Prof Walsh is of the opinion that traditional measures such as body mass index (BMI) and weight for length have limitations in this regard, as they do not provide a clear distinction between these components. Furthermore, BMI may not be reliable for assessing adiposity or obesity in paediatric populations, and it can vary significantly with age and gender.

Addressing these challenges, the PEA POD equipment offers advanced technology that allows for highly accurate quantification of infant body composition. This technological capability opens up opportunities to study the effects of early-life nutrition on growth and the developmental mechanisms that may lead to later comorbidities. So, when it comes to researching infant body weight and composition, the PEA POD equipment plays a crucial role in providing precise data and insights.

News Archive

DNA sequencer launched at the UFS
2013-11-25

Dr Gansen Pillay, Deputy Chief Executive Officer of the National Research Foundation, explaining to the scholars what will be expected of them.

The University of the Free State (UFS) can now collect immensely valuable data on drug resistance in HIV/Aids and TB with the new DNA sequencer that was launched recently at the International workshop on HIV/AIDS and TB drug resistance at the Bloemfontein Campus.

The DNA sequencer will allow the Free State province to produce viral and bacterial genetic data to fight the local development of HIV/ Aids and TB drug resistance.

The HIV and TB epidemics have expanded very fast and South Africa now has the largest HIV and TB treatment programme in the world, with over 2 million patients on treatment. However, these successful treatment programmes are now being threatened by the appearance of drug resistance.

The Free State province has been at the forefront of fighting HIV drug resistance in South Africa and has one of the most advanced treatment programmes for the management of resistance strains in the country. In addition, researchers at the University of the Free State are leading partners in the Southern African Treatment and Resistance Network (SATuRN; www.bioafrica.net/saturn), a research network that has trained over 2 000 medical officers in the treatment of drug resistance strains.

The Department of Medical Microbiology and Virology in the Medical School at the UFS has partnered with the provincial department of health, the Medical Research Council (MRC) and the Delegation of the European Union to South Africa to fund a dedicated DNA sequencer machine that will be used to generate HIV and TB drug-resistance results. This new machine will enable cutting-edge research to take place, using the data in the province and, importantly, support patients with resistance strains to have access to advanced genotypic testing techniques.

“HIV drug resistance is a very serious problem in South Africa, and the recent advances in DNA testing technology allow clinicians in the province to access drug resistance testing, which enables them to manage patients appropriately who fail treatment, and use the results to cost-effectively extend and improve patients’ lives,” says Dr Cloete van Vuuren, Specialist in Infectious Diseases at the UFS’s Faculty of Health.

Dr Dominique Goedhals, pathologist from the Department of Medical Microbiology and Virology at the UFS, adds: “We have been looking forward to expanding our work with the clinicians and researchers, using DNA sequencing to shed light on the causes and consequences of drug resistance in urban and rural settings in the province.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept